SEC Comment Letter for CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — May 26, 2017

CervoMed Inc. (CRVO) (CIK 0001053691)
Date: May 26, 2017 · CIK: 0001053691 · Accession: 0000000000-17-018562

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

May 26, 2017

Author

Dorrie Yale

Form

UPLOAD

Company

CervoMed Inc. (CRVO) (CIK 0001053691)

Letter

May 26, 2017 David Kalergis Chief Executive Officer Diffusion Pharmaceuticals Inc. 2020 Avon Court, #4 Charlottesville, VA 22902 Diffusion Pharmaceuticals Inc. Registration Statement on Form S-3 Filed May 17, 2017 File No. 333-218062Re: Dear Mr. Kalergis: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance

Show Raw Text

May 26, 2017
David Kalergis
Chief Executive Officer
Diffusion Pharmaceuticals Inc.
2020 Avon Court, #4
Charlottesville, VA 22902
Diffusion Pharmaceuticals Inc.
Registration Statement on Form S-3
Filed May 17, 2017
File No. 333-218062Re:
Dear Mr. Kalergis:
        This is to advise you that we have not reviewed and will not review your registration
statement.
        Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
        Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance

SecProbe.io